Navigation Links
Epiphany Biosciences Initiates Program to Assess Valomaciclovir (EPB-348) as Adjunctive Therapy in Multiple Sclerosis (MS)

SAN FRANCISCO, March 24 /PRNewswire/ -- Epiphany Biosciences announced today that the company plans on filing an IND with the Food and Drug Administration (FDA) to study the potential impact of using the antiviral medication valomaciclovir (EPB-348) as an adjunctive therapy in the treatment of multiple sclerosis.

Valomaciclovir has been shown to possess potent antiviral activity in vitro against a number of herpes-related viruses, including herpes simplex (HSV), Epstein-Barr virus (EBV), herpes zoster (HZV), and human herpes virus 6 (HHV-6). The drug is currently being tested in a phase 2b study in patients with acute herpes zoster infection (shingles) and in a phase 2a study in patients with acute infectious mononucleosis.

"There has been accumulating evidence that MS may be the result of multiple contributing factors, including infection by the Epstein-Barr virus," stated Fred Volinsky, MD, CEO of Epiphany. "Based on these data, we feel this is the right time to explore the potential use of valomaciclovir to help manage this illness that can affect young adults as well as children."

Multiple sclerosis is a chronic, and often progressive demyelinating illness of the central nervous system, occurring with a noted predominance among women. "MS affects approximately 2.5 million people worldwide and appears to result from an interplay between genetic and environmental factors which taken together, increase a person's likelihood of developing the disease. MS is also increasing in frequency worldwide. Some progress in managing the symptoms of MS has been achieved with the use of immunomodulatory therapies. This program would be the first foray into potentially augmenting immunomodulatory therapeutics with a medicine specifically targeted at a suspected infectious cause, the Epstein-Barr virus," commented Stephen Hauser, MD, Chair of the Department of Neurology at the University of California, San Francisco and recent recipient of John Dystel Prize awarded jointly by the American Academy of Neurology and the National MS Society for his work in the field of MS research.

"We plan to conduct viral and pharmacokinetic studies prior to the use of valomaciclovir in longer term studies in patients with MS. Valomaciclovir has exhibited a sound safety profile to date with dosages ranging from one gram to three grams daily," reports Brian Murphy, MD, Chief Medical Officer of Epiphany. "We feel that ultimately, a combination approach, especially one that would involve antiviral pharmacologic pressure on the suspected viral component of the disease, could provide patients with better long-term management, especially if coupled with immunomodulatory agents that may cause transient leukopenia."

About Epiphany Biosciences

Epiphany Biosciences is a privately-held company developing therapeutic products and diagnostic technologies that treat or help prevent the spread of pathogenic viruses, including varicella virus (VZV), Epstein-Barr Virus (EBV) and hepatitis C virus (HCV).

Contact: Fred Volinsky of Epiphany Biosciences, 415-765-7193,

SOURCE Epiphany Biosciences
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Pressure BioSciences, Inc. Provides Corporate Update
2. BIND Biosciences To Install First Siemens Simatic(R) PCS 7 Lab Process Control System in the U.S.
3. Cell Biosciences Announces First UK System Sale
4. Regado Biosciences to Present at the 2009 Wharton Healthcare Business Conference
5. Neurocrine Biosciences Reports Fourth Quarter and Year-End 2008 Results
6. Enlight Biosciences Expands to direct up to $52 Million to Transformational Enabling Technologies
7. New Jersey-Based Biotech Start-Up Nexomics Biosciences Gets Off the Ground
8. URMC, Lighthouse Biosciences Awarded U.S. Patent for Diagnostic Technology
9. URMC, Lighthouse Biosciences awarded US patent for diagnostic technology
10. Abbott Completes Acquisition of Ibis Biosciences, a Subsidiary of Isis
11. CeloNova BioSciences Receives FDA Market Approval for Embozene(TM) Color-Advanced Microspheres Embolization Platform
Post Your Comments:
(Date:11/29/2015)... , ... November 29, 2015 , ... While conventional walkers ... or provide ready access to exercise weights. Fortunately, an inventor from Uniontown, Pa., has ... TOMMY WALKER to enhance the benefits of a standard walker to improve the user’s ...
(Date:11/28/2015)... ... November 28, 2015 , ... ... and teleradiology services, has added Chris Hafey and Claude Hooton to its board ... Radiological Society of North America (RSNA) 2015 Annual Meeting and continues to strategically ...
(Date:11/27/2015)... , ... November 28, 2015 , ... There is only ... outperform our billings from last year? , This question has not been an easy ... coming to the retirement age and the younger workforce don’t share the same discipline ...
(Date:11/27/2015)... Raleigh, NC (PRWEB) , ... November 27, 2015 , ... ... most effective ways to treat it. Surviving Mesothelioma has just posted the findings ... Researchers at University Hospital Zurich analyzed the cases of 136 mesothelioma patients who were ...
(Date:11/27/2015)... Aliso Viejo, CA (PRWEB) , ... November 27, 2015 , ... ... exclusively for use in Final Cut Pro X. With ProSidebar: Fasion, video editors ... banners, or use ProSidebar as a minimalist title opener. Utilize presets featuring self-animating ...
Breaking Medicine News(10 mins):
(Date:11/29/2015)... Germany , Nov. 29, 2015  At this ... attendees to experience the most complete mobile C-arm portfolio ... display is Ziehm Vision RFD 3D, the world,s only ... cm edge length per scan volume. In addition, Ziehm ... fully motorized mobile C-arm in four axes which is ...
(Date:11/29/2015)... 2015 CIVCO Medical Solutions will demonstrate ... Radiological Society of North America ... November 29 – December 4, 2015. The ... customers unrivaled versatility, enhanced user experience and deliver ... --> --> ...
(Date:11/27/2015)... Pays-Bas, November 27, 2015 ... traitement photodynamique au Bremachlorin contre le cancer avancé. ... consistant à combiner l,immunothérapie au traitement photodynamique au ... --> Une nouvelle approche consistant à ... le cancer avancé.    Clinical ...
Breaking Medicine Technology: